{"nctId":"NCT01173718","briefTitle":"Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access","startDateStruct":{"date":"2010-07"},"conditions":["End Stage Renal Disease"],"count":138,"armGroups":[{"label":"GORE® ACUSEAL Vascular Graft","type":"EXPERIMENTAL","interventionNames":["Device: GORE® ACUSEAL Vascular Graft"]}],"interventions":[{"name":"GORE® ACUSEAL Vascular Graft","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\\>\n\n1. Patient requires the creation of a vascular access graft for hemodialysis secondary to a diagnosis of End-Stage Renal Disease. \\>\n\n   \\>\\>\n2. Patient is currently on hemodialysis or ready to begin hemodialysis within 30 days following placement of study device. \\> \\>\\>\n3. The patient must be able to have the vascular access graft placed in an upper extremity. \\>\n\n   \\>\\>\n4. The patient is 18 years of age or older. \\>\n\n   \\>\\>\n5. The patient has a reasonable expectation of remaining on hemodialysis for 12 months. \\>\n\n   \\>\\>\n6. The patient or his/her legal guardian understands the study and is willing and able to comply with follow-up requirements. \\> \\>\\>\n7. The patient or his/her legal guardian is willing to provide informed consent. \\>\n\n   \\>\\>\n\n   \\>\n\n   \\>\\>\n\n   \\>\n\n   \\>\\> Exclusion Criteria:\\>\n\n   \\>\\>\n\n<!-- -->\n\n1. The patient has a documented and unsuccessfully treated ipsilateral central venous stenosis via imaging technique.\\>\n\n   \\>\\>\n2. The patient currently has a known or suspected systemic infection.\\>\n\n   \\>\\>\n3. The patient has a known hypercoagulable or bleeding disorder or requires treatment with warfarin or heparin.\\>\n\n   \\>\\>\n4. The patient has had a previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or has known sensitivity to heparin. \\>\n\n   \\>\\>\n5. The patient is being considered for a live (living donor either related or unrelated to patient) donor kidney transplant.\\>\n\n   \\>\\>\n6. The patient is enrolled in another investigational study.\\>\n\n   \\>\\>\n7. The patient has co-morbid conditions that may limit their ability to comply with study and follow-up requirements.\\>\n\n   \\>\\>\n8. Study device is intended to be used temporarily.\\>\n\n   \\>\\>\n9. The patient has had \\>2 previous arteriovenous accesses in treatment arm.\\>\n\n   \\>\\>\n10. Patient is taking Aggrenox®.\\>\n\n    \\>\\>\n11. The patient is in need of, or is scheduled for a different vascular surgical procedure within 30 days of the study procedure.\\>\n\n    \\>\\>\n12. The patient is currently taking maintenance immunosuppressant medication such as rapamycin, mycophenolate or mycophenolic acid, prednisone(\\>10 mg), cyclosporine, tacrolimus or cyclophosphamide.\\>\n\n    \\>\\>\n13. The patient has a known hypercoagulable or bleeding disorder or requires treatment with warfarin or heparin.\\>\n\n    \\>\\>\n14. Life expectancy is less than 12 months.\\>\n\n    \\>\\>\n15. The patient is pregnant.\\>\n\n    \\>\\>\n16. The patient is a poor compliance risk (i.e. history of IV or oral drug abuse).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Patency at 6 Months","description":"Percentage of subjects free from loss of access for hemodialysis at the study access site, assessed at 6 month.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Freedom From Bleeding at 6 Months","description":"Percentage of subjects free from both major and minor bleeding events, assessed at 6-months","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Unassisted Patency at 6 Months","description":"The primary unassisted patency is defined as the percentage of subjects free from the first occurence of either access thrombosis or an access procedure performed to maintain access patency.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Event Analysis (Cumulative Patency)","description":"The cumulative patency at 6 months and time-to-loss of cumulative patency will be estimated using the Kaplan-Meier survival curve for time-to-event analysis to obtain estimates accounting for censoring.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Cannulation","description":"The time to first cannulation is defined as the time from access placement to the first cannulation of the GORE® ACUSEAL Vascular Graft.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Potential Central Venous Catheter Removal","description":"The time to potential central venous catheter removal is defined as the time from the initial study procedure to the third consecutive cannulation through the GORE® ACUSEAL Vascular Graft in which hemodialysis is carried out. The third consecutive cannulation is a surrogate endpoint for time to CVC removal. Typically, CVC removal is ordered after the third consecutive cannulation.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":74,"n":138},"commonTop":[]}}}